Literature DB >> 35032315

Thyroid disorders and cardiovascular manifestations: an update.

Stavroula A Paschou1, Evanthia Bletsa2, Panagiota K Stampouloglou2, Vasiliki Tsigkou2, Angeliki Valatsou3, Katerina Stefanaki4, Paraskevi Kazakou4, Michael Spartalis2, Eleftherios Spartalis5, Evangelos Oikonomou2, Gerasimos Siasos2.   

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing a major health, social, and economic issue. Thyroid disorders are very common and affect >10% of the adult population in total. The aim of this review is to describe the physiologic role of thyroid hormones on cardiovascular system, to present cardiovascular manifestations in patients with thyroid disorders, emphasizing in molecular mechanisms and biochemical pathways, and to summarize current knowledge of treatment options. Thyroid hormone receptors are located both in myocardium and vessels, and changes in their concentrations affect cardiovascular function. Hyperthyroidism or hypothyroidism, both clinical and subclinical, without the indicated therapeutical management, may contribute to the progression of CVD. According to recent studies, even middle changes in thyroid hormones levels increase cardiovascular mortality from 20% to 80%. In more details, thyroid disorders seem to have serious effects on the cardiovascular system via plenty mechanisms, including dyslipidemia, hypertension, systolic and diastolic myocardial dysfunction, as well endothelial dysfunction. On top of clinical thyroid disorders management, current therapeutics focus on younger patients with subclinical hypothyroidism and elderly patients with subclinical hyperthyroidism.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular disease; Heart failure; Hyperthyroidism; Hypothyroidism; Lipids; Thyroid

Mesh:

Substances:

Year:  2022        PMID: 35032315     DOI: 10.1007/s12020-022-02982-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  79 in total

1.  Subclinical thyroid dysfunction as a risk factor for cardiovascular disease.

Authors:  John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli
Journal:  Arch Intern Med       Date:  2005-11-28

Review 2.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

3.  A current appraisal of drug therapy of atherosclerosis.

Authors:  J H Moyer
Journal:  Arch Environ Health       Date:  1967-02

Review 4.  Global epidemiology of hyperthyroidism and hypothyroidism.

Authors:  Peter N Taylor; Diana Albrecht; Anna Scholz; Gala Gutierrez-Buey; John H Lazarus; Colin M Dayan; Onyebuchi E Okosieme
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

5.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Authors:  Frank L J Visseren; François Mach; Yvo M Smulders; David Carballo; Konstantinos C Koskinas; Maria Bäck; Athanase Benetos; Alessandro Biffi; José-Manuel Boavida; Davide Capodanno; Bernard Cosyns; Carolyn Crawford; Constantinos H Davos; Ileana Desormais; Emanuele Di Angelantonio; Oscar H Franco; Sigrun Halvorsen; F D Richard Hobbs; Monika Hollander; Ewa A Jankowska; Matthias Michal; Simona Sacco; Naveed Sattar; Lale Tokgozoglu; Serena Tonstad; Konstantinos P Tsioufis; Ineke van Dis; Isabelle C van Gelder; Christoph Wanner; Bryan Williams
Journal:  Eur Heart J       Date:  2021-09-07       Impact factor: 35.855

6.  The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis.

Authors:  Ane Garmendia Madariaga; Silvia Santos Palacios; Francisco Guillén-Grima; Juan C Galofré
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

7.  Subclinical hypothyroidism represents an additional risk factor for coronary artery calcification, especially in subjects with intermediate and high cardiovascular risk scores.

Authors:  Nathalie Silva; Olga Santos; Felipe Morais; Ilan Gottlieb; Macelo Hadlich; Tamara Rothstein; Milena Tauil; Nathalia Veras; Mario Vaisman; Patricia de Fátima Teixeira
Journal:  Eur J Endocrinol       Date:  2014-06-10       Impact factor: 6.664

Review 8.  Thyroid hormone regulation of metabolism.

Authors:  Rashmi Mullur; Yan-Yun Liu; Gregory A Brent
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

9.  Thyroid hormone and cardiac disease: from basic concepts to clinical application.

Authors:  Iordanis Mourouzis; Francesca Forini; Constantinos Pantos; Giorgio Iervasi
Journal:  J Thyroid Res       Date:  2011-06-19

10.  Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.

Authors:  Nicholas R Jones; Andrea K Roalfe; Ibiye Adoki; F D Richard Hobbs; Clare J Taylor
Journal:  Eur J Heart Fail       Date:  2019-09-16       Impact factor: 15.534

View more
  3 in total

Review 1.  Interplay between Fatty Acid Binding Protein 4, Fetuin-A, Retinol Binding Protein 4 and Thyroid Function in Metabolic Dysregulation.

Authors:  Daniela Dadej; Ewelina Szczepanek-Parulska; Marek Ruchała
Journal:  Metabolites       Date:  2022-03-29

2.  Editorial: Subclinical thyroid disease: present knowledge and future direction.

Authors:  Jose De Jesus Garduno Garcia; Alberto O Chavez; Daniel Elías-López; Iván Pérez-Díaz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-21       Impact factor: 6.055

3.  Management of Hypertension in the Elderly and Frail Patient.

Authors:  Luigina Guasti; Marco Ambrosetti; Marco Ferrari; Franca Marino; Marc Ferrini; Isabella Sudano; Maria Laura Tanda; Iris Parrini; Riccardo Asteggiano; Marco Cosentino
Journal:  Drugs Aging       Date:  2022-07-29       Impact factor: 4.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.